1 published article · Updated continuously
61 trials tracked for Morbid Obesity: 9 in phase 3 or 4 and 2 with published results. The most-cited published study has 10 citations.
Showing the 50 most-cited and recently-updated of 61 trials. Browse the full registry →
Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.
Bupivacaine has been investigated as an intervention in patients with morbid obesity, showing significant results in pain management; specifically, trials reported mean Visual Analogue Scale (VAS) scores of 6.60, 6.15, 4.37, 3.11, 5.85, and 4.80 [1, 3]. Additionally, the use of a combination of morphine-0.1% and levobupivacaine resulted in mean changes from baseline in pain scores of 1.4, 1.6, 1.6, 0.8, 1.1, and 0.8 9.
Surgical interventions for weight management include the Swedish Adjustable Gastric Band (SAGB). One trial showed a -35.6% change in excess body weight at 5 years post-implant with a re-operation rate of 8.91% 7. Another study on SAGB reported a 41.1% excess weight loss, though it noted a 69.6% incidence of adverse events 10.
Pharmacological management using Dapagliflozin/Metformin demonstrated significant improvements in multiple metabolic markers, including reductions in weight (p<0.05), blood pressure (p<0.05), and waist circumference (p<0.05) 8. In procedural settings for morbidly obese patients, a dural puncture epidural (DPE) showed no significant difference in the number of participants requiring interventions like asymmetric blocks or emergency general anesthesia compared to standard care (p=0.766) 4. Other procedural findings include success at low insufflation pressure during certain procedures 6 and the use of Cefazolin 5 and Rocurinum 6.
AI synthesis of 8 cited trials, updated Jun 22, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.
